NL-OMON32303已完成3 期
Extension 1 to Protocol A 2 year extension to a 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high risk post-acute myocardial infarction patients when added to optimized standard therapy - ASPIRE extension
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •See protocol for complete criteria (page 5)
- •Completed the CSPP100A2340 / ASPIRE study through visit 10 while on double-blind study drug.
排除标准
- •See protocol for complete criteria (page 5)
- •- NYHA class IV Congestive Heart Failure at Visit 1 (CSPP100A2340 Core Study Visit 10).
- •- Symptomatic hypotension, or reported systolic BP < 90 mmHg within the 24 hours prior to Visit 1.
- •- eGFR < 30 ml/min/1.73m2 using the MDRD formula at Visit 1.
研究者
相似试验
进行中（未招募）
不适用
Extension 1 to Protocol A 2 year extension to a 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high risk post-acute myocardial infarction patients when added to optimized standard therapy - NDEssential HypertensionMedDRA version: 9.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2008-001306-16-ITOVARTIS FARMA800
进行中（未招募）
不适用
A two years extension to a one year multicenter, partially blinded double dummy randomized study to evaluate the efficacy and safety of FTY720 combined with reduced dose or full dose Neoral and corticosteroids vs mycophenolate mofetil combined with full dose Neoral and corticosteroids in de novo adult renal transplant recipientsPrevention of the acute rejection in renal transplant patientMedDRA version: 6.1Level: PTClassification code 10023439EUCTR2004-004958-63-ITOVARTIS FARMA600
进行中（未招募）
不适用
A two-year extension to a one-year, multicenter, open-label, randomized study to evaluate the safety and efficacy of FTY720 combined with tacrolimus and steroids versus MMF (Cellcept) combined with tacrolimus and steroids, in de novo adult renal transplant recipients.De novo kidney transplantationEUCTR2005-000350-69-DEovartis Pharma Services AG140
进行中（未招募）
不适用
A two-year extension to a one-year, multicenter, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral and corticosteroids versus mycophenolate mofetil (MMF, CellCept) combined with full-dose Neoral and corticosteroids, in de novo adult renal transplant recipientsProphylaxis of kidney allograft rejection in de novo adult renal transplant recipientsMedDRA version: 7.0Level: LLTClassification code 10023439EUCTR2004-004377-28-SEovartis Pharma AG690
进行中（未招募）
不适用
A two-year extension to a one-year, multicenter, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral and corticosteroids versus mycophenolate mofetil (MMF, CellCept) combined with full-dose Neoral and corticosteroids, in de novo adult renal transplant recipientsProphylaxis of kidney allograft rejection in de novo adult renal transplant recipientsMedDRA version: 7.0Level: LLTClassification code 10023439EUCTR2004-004958-63-DEovartis Pharma Services AG718